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Background: Moderate to severe premenstrual syndrome (PMS) affects 8–20 percent of premenopausal women.
Previous studies suggest that high dietary vitamin D intake may reduce risk. However, vitamin D status is influenced
by both dietary vitamin D intake and sunlight exposure and the association of vitamin D status with PMS remains
unclear.
Methods: We assessed the relation of plasma 25-hydroxyvitamin D (25OHD), total calcium and parathyroid hormone
levels with risk of PMS and specific menstrual symptoms in a case–control study nested within the prospective Nurses’
Health Study II. Cases were 401 women free from PMS at baseline who developed PMS during follow-up (1991–2005).
Controls were women not experiencing PMS (1991–2005), matched 1:1 with cases on age and other factors. Timed
luteal phase blood samples were collected between 1996 and 1999 from cases and controls. We used conditional
logistic regression to model the relation of 25OHD levels with risk of PMS and individual menstrual symptoms.
Results: In analyses of all cases and controls, 25OHD levels were not associated with risk of PMS. However, results
differed when the timing of blood collection vs. PMS diagnosis was considered. Among cases who had already been
diagnosed with PMS at the time of blood collection (n = 279), 25OHD levels were positively associated with PMS,
with each 10 nmol/L change in 25OHD associated with a 13% higher risk. Among cases who developed PMS after
blood collection (n = 123), 25OHD levels were unrelated to risk of PMS overall, but inversely related to risk of specific
menstrual symptoms. For example, each 10 nmol/L increase was associated with a significant 21% lower risk of breast
tenderness (P = 0.02). Total calcium or parathyroid hormone levels were unrelated to PMS.
Conclusions: 25OHD levels were not associated with overall risk of PMS. The positive association observed among
women already experiencing PMS at the time of 25OHD measurement is likely due to confounding by indication
related to use of dietary supplements to treat menstrual symptoms. Results from prospective analyses, which were less
likely influenced by this bias, suggest that higher 25OHD levels may be inversely related to the development of specific
menstrual symptoms.
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Approximately 8-20% percent of premenopausal women
experience premenstrual syndrome (PMS), [1,2] a disorder
of moderate to severe symptoms in the luteal phase of the
menstrual cycle that substantially interfere with normal life
activities and interpersonal relationships [3]. Symptoms are
diverse, and commonly include affective symptoms such as
irritability, mood swings, anxiety and depression; physical
symptoms such as breast tenderness, bloating, and head-
aches; and behavioral symptoms such as insomnia, changes
in appetite, and difficulty concentrating. While pharmaco-
logic treatments including anti-depressants and oral con-
traceptives are frequently used to treat PMS, these have
substantial side effects and none has a reported efficacy
greater than 60-70% [2,3]. Because of these limitations,
effective non-pharmaceutical strategies for preventing
and treating PMS are needed.
Previous studies have evaluated the role of vitamin D
in preventing and/or treating mood and gynecologic dis-
orders that share common features with PMS. Multiple
studies have reported inverse associations between vita-
min D status and risk of depression, [4,5] fibromyalgia,
[6] dysmenorrhea, [7] and uterine fibroids [8,9]. How-
ever, it remains unknown whether vitamin D may be
useful for preventing or treating PMS. Our research
group previously reported that women who consumed
approximately 400 IU of vitamin D per day had a signifi-
cant 40% lower risk of being diagnosed with PMS in the
next 2–4 years, as compared to women consuming ap-
proximately 100 IU/day [10]. This association was present
even after adjustment for calcium, which has been shown
to beneficially impact PMS symptoms in some [11-14] but
not all studies [15]. While these results suggest that
vitamin D may be related to the development of PMS,
many questions remain and must be addressed before
vitamin D can be recommended for PMS. Vitamin D sta-
tus is the product of cutaneous vitamin D production and
not just dietary intake. Correlations of dietary vitamin D
intake with the main circulating vitamin D metabolite,
25-hydroxyvitamin D (25OHD), are relatively low, [16]
indicating that many factors influence vitamin D meta-
bolism and availability [17,18]. Thus, assessing dietary
vitamin D intake alone may be insufficient to accurately
characterize a woman’s vitamin D status.
Few studies have evaluated how 25OHD levels are asso-
ciated with PMS or with premenstrual dysphoric disorder
(PMDD), and results have been inconsistent [19-21]. Im-
portantly, because previous studies have been limited to
women already experiencing PMS at the time of their
25OHD measurement, results from these studies may be
confounded by patients’ use of vitamin D or multivitamin
supplements or other dietary changes to treat PMS symp-
toms, as is currently recommended [22,23]. Prospective
studies evaluating 25OHD levels in women prior to PMSdevelopment are needed to better understand whether
vitamin D may be etiologically related to the development
of PMS.
We have evaluated whether plasma levels of 25OHD,
along with two vitamin D-related biomarkers (total cal-
cium and parathyroid hormone), are associated with
PMS among a subset of participants in the Nurses’
Health Study II (NHS2). We have assessed relations
overall, and after taking the timing of 25OHD measure-
ment vs. PMS diagnosis into consideration. Finally,
because the physical, affective, and behavioral symptoms of
PMS likely have different etiologies, we have assessed
whether 25OHD levels are differently associated with
specific symptoms of PMS.
Methods
Study population
The NHS2 is an ongoing prospective cohort study of
116,686 US female registered nurses who responded to a
mailed questionnaire in 1989 when they were 25–42 years
old. On the baseline questionnaire, participants provided
information on their medical history and health-related
behaviors including smoking and oral contraceptive use.
Cohort members have completed questionnaires every
two years thereafter to update information on risk factors
and to identify new diagnoses of disease. All research pro-
tocols for the NHS2, under which data for the present
study were collected, were approved by the Institutional
Review Board at Brigham and Women’s Hospital, Boston,
MA. Additionally, protocols specific to the data analyses
included in this project were approved by Institutional
Review Boards at Brigham and Women’s Hospital and
the University of Massachusetts. The NHS2 is not a
publically-available database, but access to raw data is
considered for sharing under established protocols in
place at the Channing Laboratory, Brigham and Women’s
Hospital in compliance with the NIH Grants Policy on
Sharing Unique Research Resources.
Assessment of premenstrual syndrome
Women included in this analysis participated in the
NHS2 PMS Sub-Study, described in detail previously
[10,24]. Briefly, we identified all NHS2 members who
had not reported a diagnosis of PMS on their main
NHS2 questionnaire in either 1989 or 1991, and were
thus at risk for being diagnosed with PMS during
follow-up. We then identified all premenopausal women
who reported on a NHS2 questionnaire between 1991
and 2005 that they had been newly diagnosed with PMS
by a physician (n = 4,108; Figure 1). As a comparison
group, we randomly selected 3,248 premenopausal women
who did not report PMS during the follow-up period
(1991–2005). To reduce the likelihood of including women
with PMS-type symptoms caused by conditions other than
Figure 1 Selection of Nurses’ Health Study II participants into the premenstrual syndrome Sub-study and analysis of 25-hydroxyvitamin D
level and risk of PMS.
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reported: a diagnosis of cancer other than non-melanoma
skin cancer; hysterectomy; infertility; endometriosis; or
menstrual cycles that were too irregular to determine
length.
Participants were sent a questionnaire based on the
Calendar of Premenstrual Experiences, [25] on which we
assessed the occurrence of 26 physical, behavioral and
affective symptoms, symptom timing during the men-
strual cycle, and the impact of symptoms on multiple
domains of daily functioning. Completed questionnaires
were received from 3,579 (87%) of the women self-
reporting PMS and 3,087 (95%) women in the compari-
son group. We used responses to further limit our case
group to women who met established criteria for moder-
ate to severe PMS [25]. Case criteria included: 1) the oc-
currence of at least one physical/behavioral and one
affective menstrual symptom; 2) overall symptom seve-
rity of moderate or severe, or symptom impact on one or
more life activities and social relationships rated as moder-
ate or severe; 3) symptoms beginning within 14 days be-
fore onset of menses; 4) symptoms ending within 4 days
after onset of menses; and 5) symptoms absent in the week
after menses ends. Overall, 1,257 (35%) self-reported cases
met these additional criteria (Figure 1). The proportion of
self-reported PMS cases meeting our validation criteria is
consistent with those of other recent population-based
studies of PMS and calcium/vitamin D [12,19].
We also used menstrual symptom questionnaires to
further limit the comparison group to women who con-
firmed that they experienced no menstrual symptoms or
only mild symptoms of no personal impact. Ultimately,2,463 (80%) comparison women met these control cri-
teria. Women who did not meet either case or control
criteria were excluded from further analysis. This pro-
cedure allowed us to compare women at extreme ends
of the spectrum of menstrual symptom experience,
thereby minimizing the likelihood of misclassification
between cases and controls.
The validity of our approach to identifying PMS cases
and controls was assessed previously among 135 sub-
study members first reporting PMS in 2001 and 371 not
reporting PMS (1989–2001) [24]. Cases meeting our cri-
teria for PMS were very similar to cases also reporting
clinician-supervised prospective symptom charting, in
terms of symptom frequency (e.g., mean number of
physical symptoms: 5.5 vs. 6.1, P > 0.05), timing of occur-
rence (e.g., mean number of days symptoms began be-
fore onset of menses: 5.7 vs. 6.1, P > 0.05), and severity
(e.g., symptoms caused moderate-severe social isolation:
10% vs. 17%, P > 0.05). Furthermore, odds ratios for the
associations of age and calcium intake with PMS risk
using both case definitions were nearly identical, sug-
gesting that our method is comparable to prospective
charting in its ability to classify PMS cases and controls
in large epidemiologic studies.
Blood sample collection
From 1996–1999, all members of the NHS2 cohort who
had not been diagnosed with cancer were invited to pro-
vide blood samples [26]. Women who were premeno-
pausal, not using oral contraceptives or other hormones,
and who had not been pregnant or breast feeding in the
past 6 months were asked to collect two timed blood
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phase sample, used in the present analysis, was col-
lected 7–9 days before the anticipated start of the next
menstrual period. We sent women the supplies needed
to collect and return samples via overnight courier, in-
cluding heparinized tubes and an ice pack to keep
samples cool. Upon receipt, samples were centrifuged,
separated into blood components, and archived
at -130°C or colder. Samples were ultimately received
from 29,611 NHS2 members. Participants providing a
blood sample did not differ from the main NHS2 co-
hort in terms of body mass index (26 vs. 26 kg/m2),
ever smoking (34% vs. 36%), history of oral contracep-
tive use (86% vs. 88%), parity (1.9 vs. 1.9 children) and
other factors [26].
Of the 1,257 PMS cases included in the PMS Sub-
study, 401 provided blood samples (Figure 1). Cases
providing blood samples did not differ from those not
providing blood samples (n = 856) in terms of age in
1999 (42 vs. 42 years), body mass index (26.0 vs.
26.6 kg/m2), ever smoking (42% vs. 38%), vitamin D intake
(378 vs. 380 IU/day) and other factors (all P > 0.05). Blood
samples were collected before PMS diagnosis for 123
cases (median duration between blood collection and later
diagnosis = 28 months). For the remaining 279 cases,
blood was collected after PMS diagnosis (median duration
between diagnosis and later blood collection = 22 months).
We then matched cases 1:1 with controls from the PMS
Sub-Study by age, month of blood collection and follow-
up time. If more than one control met matching criteria
for a single case, control selection among eligible matches
was made randomly.Laboratory measurement
Plasma samples were analyzed for 25OHD, total calcium
and intact parathyroid hormone (iPTH) levels in the la-
boratory of Dr. Nader Rifai (Children’s Hospital, Boston,
MA). 25OHD was measured by an enzyme immuno-
assay from Immunodiagnostic Systems Inc. (Fountain
Hills, AZ). This assay is primarily a measure of the D3
isoform of 25OHD, but is also cross-reactive for the D2
isoform. Cross-reactivity for the two isoforms are 100%
(D3) and 75% (D2). Total calcium was measured by a
colorimetric assay on the Hitachi 917 analyzer using
Roche reagents (Roche Diagnostics, Indianapolis, IN).
Intact PTH was measured by an electrochemilumines-
cence immunoassay on the 2010 Elecsys autoanalyzer
(Roche Diagnostics, Indianapolis, IN). Case and control
pairs were blinded, assayed together, randomly ordered
within boxes. We also included blinded split samples
from a plasma pool to assess quality control. Coefficients
of variation were 8% for 25OHD, 5% for total calcium,
and 14% for iPTH.Assessment of other factors
Information on a variety of demographic, reproductive
and lifestyle factors has been collected regularly from
NHS2 members. Factors measured at baseline included
age, race/ethnicity, skin type/pigmentation, height, and
age at menarche. Information on full term pregnancies,
age at first birth, oral contraceptive use, and smoking
history was collected at baseline and updated every two
years. Participants reported their current weight on each
biennial questionnaire, which we used to calculate body
mass index (BMI; weight in kg/height in meters squared).
Participation in physical activity was measured in 1991,
1997 and 2001 by asking how much time women spent
each week participating in specific recreational activities.
Responses were used to calculate metabolic equivalent
task (MET) hours of activity [27].
Use of medications, including anti-depressants, was
assessed from 1993 onward. History of clinician-diagnosed
depression was reported on main NHS2 questionnaires in
2003 and 2005, as well as on the menstrual symptom
questionnaire. Socioeconomic factors including mother’s
and father’s education level were reported in 2005. Food
and nutrient intake was assessed every four years by vali-
dated semi-quantitative foods frequency questionnaire,
[28] and used to estimate intake of calcium, vitamin D, po-
tassium, B vitamins and other nutrients from foods and
supplements. In 1999, dose categories for calcium on the
food frequency questionnaire were none, <400 mg/day,
400-900 mg/day, 901-1300 mg/day, and ≥1301 mg/day.
Use of vitamin D supplements was measured as yes/no.
All nutrients were adjusted for total energy intake using
the residual method [29].
Statistical analysis
All statistical analyses were conducted with SAS (SAS
Institute, Inc., Cary, North Carolina). We first compared
characteristics at the time of blood collection of all PMS
cases vs. controls using t-tests. We characterized vitamin
D status in several ways. First, to assess the impact of
vitamin D deficiency vs. sufficiency on risk, we divided
participants into groups based on current Institute of
Medicine guidelines (<50 vs. ≥ 50 nmol/L) [30]. To evalu-
ate the impact of more extreme levels of 25OHD on risk,
we divided participants into quintiles based on the distri-
bution in the control group. Finally, we assessed the linear
relation of 25OHD with risk of PMS by modeling 25OHD
as a continuous variable. In each analysis, we estimated
odds ratios (OR) for PMS by 25OHD level using condi-
tional logistic regression, and calculated 95% confidence
intervals (CI). P values <0.05 were considered statistically
significant.
We used multivariable conditional logistic regression
to control for the effects of other factors that could con-
found the vitamin D-PMS relationship, or that have been
Table 1 Characteristics of premenstrual syndrome cases







Mean (SD) Mean (SD)
Age (years) 40.6 (4.0) 40.7 (3.8) 0.94
Body mass index (kg/m2) 25.7 (5.8) 25.4 (5.8) 0.50
Body mass index at age 18 (kg/m2) 21.5 (3.4) 21.4 (3.5) 0.81
Age at menarche (years) 12.5 (1.4) 12.4 (1.5) 0.45
Number of full term pregnancies 2.0 (1.2) 2.0 (1.3) 0.43
Age at first birth (years)* 26.2 (4.2) 26.7 (4.1) 0.11
Physical activity (MET/wk) 18.7 (19.4) 20.0 (20.8) 0.36
Alcohol intake (grams/day) 4.6 (6.8) 3.7 (6.5) 0.05
% %
White race 96.0 98.8 0.02
Mother had > high school education 31.9 39.9 0.02
More than 5 moles on lower leg† 15.5 17.0 0.57
Low UV radiation index region of US 22.2 26.0 0.22
Current smoker 11.2 4.7 <0.001
Former smoker 30.7 15.7 <0.001
Tubal ligation 31.1 25.2 0.06
Significant childhood trauma 18.1 5.6 <0.001
Antidepressant use& 14.7 6.2 <0.001
Ever used oral contraceptives 86.5 77.3 <0.001
Calcium/vitamin D supplement use 41.4 39.9 0.67
B vitamin supplement use 17.7 10.0 0.002
Regular multivitamin use 48.9 44.1 0.18
Biomarkers Mean (SD) Mean (SD)
25-hydroxyvitamin D (nmol/L) 66.5 (20.5) 64.8 (19.9) 0.24
Total calcium (mg/dL) 9.74 (0.39) 9.72 (0.38) 0.64
Intact Parathyroid hormone (pg/mL) 31.2 (11.5) 31.1 (11.6) 0.92
*Among parous women (n = 326 controls, 340 cases).
†At baseline; a measure of light skin tone.
&Use before diagnosis (cases).
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factors that could change during follow-up (e.g., physical
activity, BMI, smoking status), we modeled level at the
time of blood collection. In addition to matching factors
(age, month of blood collection and follow-up time), our
final model included race/ethnicity, geographic region of
residence, number of moles on lower leg (a proxy mea-
sure of skin tone, sun sensitivity, and potentially of early
life sun exposure [31,32]), BMI, physical activity, alcohol
intake, current and former smoking, history of oral
contraceptive use, maternal education, antidepressant
use, childhood trauma, and vitamin B6 intake. We re-
peated these analyses evaluating the association of total
calcium and iPTH levels with risk of PMS, and adjusted
each biomarker for the effects of the others.
The association of biomarkers and PMS could be in-
fluenced by many issues relating to timing of blood col-
lection vs. PMS diagnosis, including use of calcium and
vitamin D supplements to treat existing PMS. We thus
repeated our main analyses separately for cases who had
already been diagnosed with PMS by the time of blood
collection and cases with blood collected before their
PMS diagnosis. To maximize power for these compari-
sons, we compared each case group to all controls using
unconditional logistic regression, and further adjusted
for age, season of blood collection, and follow-up time
in our multivariable models.
Finally, to determine if 25OHD levels were differently
related to individual symptoms of PMS, we assessed risk
of each symptom queried. In these analyses, we com-
pared cases experiencing each symptom to controls not
experiencing the symptom in multivariable uncondi-
tional logistic regression models. Finally, we conducted a
sensitivity analysis excluding women reporting any clin-
ical diagnosis of depression during follow-up (n = 173
cases and 63 controls excluded), to determine whether
associations were robust to potential misclassification of
depression as PMS.
Results
Characteristics of PMS cases and controls measured at
the time of blood collection are presented in Table 1.
Overall, cases were more likely than controls to be
current or former smokers (P < 0.001 for both). Cases
had a marginally higher mean daily alcohol intake (4.6 vs.
3.7 g/day; P = 0.05), and were more likely to report signifi-
cant trauma in childhood (18.1% vs. 5.6%; P < 0.0001).
Though the study population was racially homogenous
overall, cases and controls differed significantly in the pro-
portion of participants reporting white race (P = 0.02).
Both anti-depressant use and oral contraceptive use
were more commonly reported by cases than controls
(P < 0.001 for both), as was use of B vitamin supple-
ments (P = 0.002). Cases and controls did not differ byage, BMI, age at menarche, or physical activity. Mean
levels of vitamin D-related biomarkers did not differ
between cases and controls.
In our main analyses of all PMS cases and their
matched controls, we did not find plasma levels of
25OHD, total calcium or parathyroid hormone to be as-
sociated with PMS (Table 2). In unadjusted analyses, the
OR for women in the highest quintile of 25OHD
(median = 91.6 nmol/L) was 1.26 (95% CI = 0.79 – 2.02)
compared to the lowest quintile (median = 42.4 nmol/L).
Adjustment for other factors including BMI, smoking,
and physical activity did not materially alter results. For
example, after adjustment, women in the highest quintile
of 25OHD had an OR of 1.16 (95% CI = 0.60 – 2.41).
Table 2 Odds ratios (OR) for premenstrual syndrome by blood levels of vitamin D-related biomarkers, NHS2 PMS
Sub-study
Factor Cases Controls Unadjusted OR (95% CI) MV adjusted OR* (95% CI)
25-hydroxyvitamin D
Deficiency vs. Sufficiency
< 50 nmol/L 86 90 1.00 1.00
≥ 50 nmol/L 315 311 1.07 (0.75 – 1.53) 1.14 (0.77 – 1.68)
Quintiles (median, nmol/L)
Q1 (42.4) 72 81 1.00 1.00
Q2 (53.5) 76 79 1.10 (0.70 – 1.74) 1.02 (0.56 – 1.84)
Q3 (62.6) 72 81 1.03 (0.65 – 1.63) 1.23 (0.67 – 2.29)
Q4 (73.6) 96 79 1.44 (0.90 – 2.30) 1.25 (0.65 – 2.41)
Q5 (91.6) 85 81 1.26 (0.79 – 2.02) 1.16 (0.60 – 2.41)
Per 10 nmol/L change 401 401 1.05 (0.97 – 1.13) 1.04 (0.93 – 2.25)
Total calcium
Quintiles (median, mg/dL)
Q1 (9.3) 79 79 1.00 1.00
Q2 (9.6) 83 83 1.00 (0.65 – 1.55) 1.13 (0.63 – 2.02)
Q3 (9.7) 90 101 0.91 (0.59 – 1.39) 0.91 (0.52 – 1.60)
Q4 (9.9) 67 63 1.09 (0.67 – 1.77) 1.28 (0.69 – 2.37)
Q5 (10.2) 82 75 1.12 (0.69 – 1.80) 1.03 (0.55 – 1.94)
Per 1 mg/dL change 401 401 1.11 (0.74 – 1.67) 1.18 (0.70 – 2.00)
iPTH
Quintiles (median, pg/mL)
Q1 (19.4) 81 80 1.00 1.00
Q2 (23.8) 59 79 0.72 (0.46 – 1.15) 0.70 (0.38 – 1.27)
Q3 (28.5) 96 79 1.21 (0.79 – 1.85) 1.50 (0.85 – 2.64)
Q4 (34.5) 80 80 1.00 (0.64 – 1.55) 1.16 (0.65 – 2.08)
Q5 (46.9) 85 83 1.01 (0.66 – 1.55) 0.89 (0.50 – 1.58)
Per 10 pg/mL change 401 401 1.01 (0.89 – 1.13) 0.93 (0.78 – 1.10)
*Multivariable (MV) OR from conditional logistic regression adjusted for race/ethnicity, geographic region, BMI, physical activity, alcohol intake, smoking status,
number of moles on leg, oral contraceptive use, maternal education, antidepressant use, significant childhood trauma, and vitamin B6 intake. Each biomarker
adjusted for the others (continuous levels).
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indicating vitamin D deficiency vs. sufficiency (i.e., <50
vs. ≥50 nmol/L) were similarly null. Neither total cal-
cium nor iPTH levels were associated with risk of PMS.
We then evaluated associations separately by timing of
25OHD measurement vs. PMS diagnosis (Table 3).
25OHD levels were higher in cases who had already been
diagnosed with PMS as the time of their blood collection
(67.9 nmol/L) as compared to controls (64.8 nmol/L), and
25OHD was positively associated with PMS risk. Specifi-
cally, each 10 nmol/L increase in 25OHD was associated
with a 13% higher risk of PMS (95% CI = 1.03 – 1.25). In
contrast, 25OHD levels were not associated with risk in
cases with blood collected before diagnosis.
Relations of 25OHD levels with individual menstrual
symptoms also varied by timing of blood collection.Among women with 25OHD measured before they
were diagnosed with PMS, plasma 25OHD levels were
inversely related to risk of developing breast tender-
ness, fatigue, diarrhea and/or constipation, and depres-
sion (all P < 0.05; Table 3). For example, each 10 nmol/L
increase in 25OHD level was associated with a significant
21% lower risk of developing breast tenderness (P = 0.02),
and a significant 19% lower risk of depression (P = 0.047).
In contrast, among women who already had PMS at
the time of blood collection, 25OHD was positively
associated with risk of diarrhea/constipation, food
cravings, appetite changes, and a variety of affective
symptoms (all P < 0.05). For example, each 10 nmol/L
increase in 25OHD level was associated with a signifi-
cant 19% higher risk of anxiety and irritability (P < 0.01
for both).
Table 3 Odds ratios for premenstrual syndrome and individual menstrual symptoms, stratified by timing of 25OHD
measurement vs. PMS diagnosis
25OHD measured before PMS diagnosis 25OHD measured after PMS diagnosis
Outcome Cases* MV OR† (95% CI) for 10 nmol/L
change in 25OHD
Cases* MV OR† (95% CI) for 10 nmol/L
change in 25OHD
Premenstrual Syndrome 123 0.97 (0.85 – 1.11) 279 1.13 (1.03 – 1.25)
Physical & behavioral menstrual symptoms
Swelling of extremities 27 0.77 (0.57 – 1.06) 58 1.12 (0.96 – 1.31)
Breast tenderness 79 0.79 (0.65 – 0.96) 211 1.05 (0.93 – 1.19)
Fatigue 64 0.80 (0.66 – 0.97) 153 1.10 (0.99 – 1.23)
Diarrhea/constipation 50 0.80 (0.65 – 0.98) 108 1.13 (1.00 – 1.29)
Backache 41 0.85 (0.67 – 1.07) 104 1.11 (0.98 – 1.26)
Bloating 77 0.85 (0.71 – 1.03) 181 1.10 (0.99 – 1.23)
Hot flashes 16 0.86 (0.59 – 1.25) 15 1.09 (0.79 – 1.52)
Palpitations 15 0.90 (0.62 – 1.32) 22 1.14 (0.90 – 1.45)
Food cravings 82 0.92 (0.78 – 1.09) 204 1.15 (1.03 – 1.29)
Appetite changes 68 0.93 (0.79 – 1.10) 163 1.17 (1.04 – 1.31)
Forgetfulness 24 0.96 (0.72 – 1.28) 58 1.15 (0.99 – 1.34)
Insomnia 33 0.95 (0.76 – 1.20) 47 1.15 (0.97 – 1.36)
Acne 36 0.97 (0.76 – 1.24) 96 1.14 (1.01 – 1.29)
Headache 58 1.02 (0.85 – 1.23) 125 1.07 (0.95 – 1.22)
Affective menstrual symptoms
Depression 51 0.81 (0.66 – 1.00) 117 1.10 (0.98 – 1.24)
Anxiety 35 0.82 (0.63 – 1.06) 91 1.19 (1.04 – 1.35)
Tendency to cry easily 59 0.92 (0.76 – 1.12) 158 1.13 (1.01 – 1.27)
Anger 68 0.94 (0.78 – 1.13) 165 1.12 (1.01 – 1.25)
Irritability 110 0.95 (0.81 – 1.11) 235 1.19 (1.07 – 1.34)
Hypersensitivity 37 0.95 (0.76 – 1.19) 112 1.14 (1.01 – 1.29)
Cramping 46 0.98 (0.80 – 1.20) 92 1.03 (0.90 – 1.19)
Mood swings 76 1.00 (0.85 – 1.17) 191 1.15 (1.04 – 1.28)
Desire for aloneness 38 1.01 (0.80 – 1.28) 113 1.14 (1.00 – 1.29)
Odds ratios (OR) correspond to change in risk of PMS or individual symptoms for each 10 nmol/L change in 25OHD level. OR significant at P < 0.05 are bolded.
*Number of PMS cases reporting specific symptom. Results for symptoms of dizziness, nausea, confusion are not shown, as these symptoms were reported by ≤10 cases.
†Multivariable (MV) OR from unconditional logistic regression adjusted for age, season of blood collection, race/ethnicity, geographic region, BMI at blood draw,
physical activity, alcohol intake, smoking status at blood collection, number of moles on leg, oral contraceptive use, maternal education, antidepressant use,
significant childhood trauma, and vitamin B6 intake, and plasma levels of total calcium and parathyroid hormone.
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cluding women reporting a diagnosis of depression du-
ring follow-up were similar to the main analyses. For
example, the OR for each 10 nmol/L change in 25OHD
was 1.08 (95% CI = 0.98 – 1.19).
Discussion
Overall, we found no association between plasma levels
of 25OHD and risk of PMS in our longitudinal study.
However, results differed somewhat based on the timing
of blood measurement in relation to PMS diagnosis.
Among women who had already been diagnosed with
PMS by the time of blood collection, 25OHD levels were
positively associated with PMS risk. In contrast, amongwomen diagnosed with PMS after blood draw, 25OHD
levels were not associated with future risk of developing
PMS.
The observed positive association of 25OHD with PMS
risk was contrary to our hypothesis, and reasons for this
finding are unclear. One potential explanation is that
women experiencing PMS may treat their symptoms with
calcium and vitamin D supplements, or multivitamins
containing these nutrients, as is currently recommended
by the American Congress of Obstetricians and Gynecolo-
gists and other groups [22,23]. Consequently, 25OHD
levels would elevated in PMS cases due to differences in
supplementation practices, and this type of confounding
by indication would bias results. In our study, mean
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who had PMS at blood collection (67.9 nmol/L) compared
to those not yet diagnosed (63.2 nmol/L; P = 0.04), sug-
gesting that supplementation, diet and/or behaviors influ-
encing vitamin D status differed between case groups.
We further explored this hypothesis in post hoc ana-
lyses. At the time of blood collection, calcium and vita-
min D supplement use was reported by 43.5% of women
already experiencing PMS, compared to 36.6% of women
not yet diagnosed (P = 0.19). Multivitamin use also var-
ied slightly between groups (50.% vs. 44.7%, respectively;
P = 0.27). This finding is consistent with results from
Thys-Jacobs et al. [20], who reported non-significantly
higher use of calcium supplements (46% vs. 32%) and
vitamin D supplements (41% vs. 30%) among women
with PMDD compared to symptom-free controls [20].
Among calcium supplement users in our population,
56% reported taking 400–900 mg/day, while 36% re-
ported taking >900 mg/day; this level of supplementa-
tion may have considerable impact on associations.
When we took supplementation practices into consid-
eration among cases already diagnosed with PMS at the
time of blood collection, we found the positive associ-
ation to be limited to women using supplements (OR for
each 10 nmol/L change = 1.19; P = 0.002). In contrast,
among non-users of supplements, 25OHD levels were
unrelated to risk (OR = 1.03; P = 0.67). These results sup-
port the hypothesis that women experiencing PMS may
be self-medicating with dietary supplements. This inter-
pretation is also consistent with results from a previous
study of B vitamin supplementation and PMS in our
population, in which we found vitamin B6 supplement
use to be more common among women already experi-
encing PMS than among women not yet diagnosed with
PMS [33]. The likelihood of confounding by indication
suggests a need for caution in interpreting results from
case–control and cross-sectional studies of nutritional
factors and PMS. It also underscores the importance of
evaluating these relations prospectively whenever pos-
sible, to minimize the chance of bias.
Over 100 different menstrual symptoms may occur in
PMS, [34] and the specific symptoms experienced by indi-
vidual women may differ substantially. Because physical,
affective, and behavioral symptoms likely have different eti-
ologies, it is may be important to evaluate the associations
of etiologic factors with individual symptoms and symptom
clusters separately. This hypothesis is supported by ran-
domized trials of pharmacologic therapies for PMS, as
reviewed by Halbreich et al. [35], which demonstrate sub-
stantial variation in treatment response between symptom
profiles. For example, selective serotonin reuptake inhibi-
tors appear most beneficial to women experiencing mood
symptoms, especially irritability, and behavioral symptoms,
but are less effective for treating physical symptoms.Similarly, associations of vitamin D with specific symp-
toms may vary. In the present analysis, among women not
yet diagnosed with PMS at blood collection, we found
25OHD level to be associated with significantly lower risk
of developing breast tenderness, diarrhea/constipation, fa-
tigue and depression (P < 0.05) and possibly with swelling
of extremities and bloating (P ≤ 0.11). It is possible that
some of these findings may be due to chance, given the
relatively large numbers of comparisons we made. Alter-
natively, differences in observed associations suggest that
vitamin D may be associated with some symptoms but
not others. For example, clinical studies of PMS suggest
that dysfunction of the renin-angiotensin-aldosterone sys-
tem (RAAS) is involved in premenstrual edema symptoms
such as abdominal bloating, swelling of extremities, and
breast tenderness [36]. Vitamin D deficiency is also as-
sociated with increased RAAS function, contributing to
increased fluid balance, blood pressure changes, and
hypertension [37,38]. Furthermore, an inverse relation
between 25OHD levels and premenstrual depression
would be consistent with the literature suggesting that
vitamin D may lower risk of unipolar depression [39]. It
therefore seems plausible that vitamin D may specific-
ally influence menstrual depression and symptoms re-
lated to fluid balance, but not other symptoms. This
should be explored in future studies.
Our study has several potential limitations requiring
consideration. First, our ability to assess the relation of
vitamin D-related biomarkers and PMS may have been
limited by access to only a single blood sample collected
several years before or after PMS diagnosis. It is possible
that the 25OHD level measured in this sample does not
reflect long-term vitamin D status. Multiple studies have
evaluated the stability of 25OHD within individuals over
time [40-43]. For example, in the Nurses’ Health Study,
the intraclass correlation comparing three measurements
of 25OHD levels collected over 3 years was 0.72 (95%
CI = 0.62-0.80) [40]. However, most studies of vitamin D
stability in women have been conducted in postmeno-
pausal women or have not directly evaluated variation
by menopausal status [40,42,43]. In one study evaluating
blood samples drawn before and after menopause in 34
women (median time between samples = 5.8 years) the
correlation for 25OHD was 0.39 (P < 0.05), suggesting
that levels may be stable over many years, even in the
context of substantial changes in levels of estradiol and
other sex steroid hormones [41]. While these data sug-
gest that a single 25OHD measurement can accurately
represent vitamin D status over multiple years, add-
itional studies specifically evaluating relations in pre-
menopausal women are needed.
Additionally, we were unable to consider the effect of
vitamin D binding protein concentrations, which recent
studies suggest may importantly affect the bioavailability
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surements and health outcomes [44]. Future studies of
vitamin D status and PMS risk should incorporate this
important parameter. It is important to note that for our
prospective analyses, misclassification resulting from the
use of a single 25OHD measurement to represent long-
term vitamin D status is likely to be non-differential with
respect to PMS diagnosis. Consequently, this type of bias
would lead to an underestimation of the relation of vita-
min D and PMS, as opposed to exaggerating associa-
tions. Additional prospective studies, including clinical
trials, are needed to clarify the impact of timing of
25OHD measurement on the association of vitamin D
and the development of menstrual symptoms and PMS.
Due to the collection and storage protocol used in the
NHS2, we were unable to measure ionized calcium, which
is a preferred measure of calcium status in clinical popula-
tions, and to measure protein stores as they impact cal-
cium status [45]. This may have contributed to some
misclassification of the association of calcium status with
PMS risk. While we adjusted for a variety of dietary and
lifestyle factors that could confound the association of
vitamin D and PMS risk, we were unable to separately
evaluate indoor and outdoor physical activity (which could
differently affect 25OHD levels), or comprehensively as-
sess other aspects of sun exposure. Though we included
race/ethnicity, geographic region of residence, and num-
ber of moles on lower leg in our multivariable regression
models, these factors are likely imprecise measures of sun
exposure and some residual confounding may persist.
Our study of PMS is nested within a large, ongoing
prospective cohort study of over 116,000 women. Con-
sequently, we were unable to use prospective symptom
diaries to classify PMS, as is recommended by the
International Society for Premenstrual Disorders [46].
However, we used established criteria to identify women
meeting strict criteria for moderate to severe PMS [25] as
well as to define a comparison group of women experien-
cing no menstrual symptoms or few symptoms with no
personal impact. Women meeting neither case nor control
criteria were excluded from analysis. Thus, the likelihood
of misclassification between cases and controls is minimal
and is unlikely to bias our findings. Additionally, when we
excluded women reporting a diagnosis of depression during
follow-up, results were very similar to the main analysis.
This suggests that associations were robust to potential
misclassification of depression as PMS, or to the impact of
comorbid depression on the vitamin D – PMS relation.
Conclusions
In summary, we did not find 25OHD levels consistent
with current IOM guidelines for vitamin D sufficiency to
be associated with overall risk of PMS risk. The positive
association of 25OHD and risk we observed amongwomen already experiencing PMS at the time of vitamin
D measurement is likely due to confounding by indica-
tion resulting from the use of dietary supplements to
treat menstrual symptoms. Results from prospective
analyses, which were likely less influenced by this bias,
suggest that higher 25OHD levels may be inversely re-
lated to the development of specific menstrual symp-
toms. Additional prospective studies of vitamin D for
the treatment and prevention of PMS are warranted.
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